All In Biotech

Drug Trial Radar · NCT04230499

Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Phase IIa Trial of Encapsulated Rapamycin (eRapa) to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Jan 18, 2021

Primary completion

Dec 11, 2024

Study completion May 22, 2025

Sponsor

Lead sponsor
Rapamycin Holdings Inc.Industry
Sponsor type
Industry
Collaborators
Cancer Insight, LLC; Biodexa Pharmaceuticals
First posted
Jan 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden.

Conditions

  • Familial Adenomatous Polyposis

Interventions

  • Encapsulated Rapamycin (eRapa)Drug

    eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Colorectal Polyp Burden at Month 6Time frame: 6 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Michigan Medicine

    Ann Arbor, Michigan

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • UT Health

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.